Noticias del mercado de valores

Últimas noticias financieras · Actualizado Jul 11, 2026

OLPX
▼ bear…

¿Está Olaplex Holdings, Inc. (OLPX) entre las Mejores Penny Stocks en Ascenso para Comprar Ahora?

Is Olaplex Holdings, Inc. (OLPX) among the Best Up and Coming Penny Stocks to Buy Now?

The panel consensus is bearish on Olaplex (OLPX), citing concerns about the sustainability of its Q1 revenue beat, the uncertainty …

Yahoo Finance · May 31, 2026
BZAI
▼ bear…

Aquí está el motivo por el que Blaize Holdings, Inc. (BZAI) está entre las mejores acciones penny en alza para comprar ahora

Here is why Blaize Holdings, Inc. (BZAI) is among the Best Up and Coming Penny Stocks to Buy Now

The panel consensus is bearish on Blaize Holdings (BZAI), citing acute concentration risk due to memory bottlenecks and a single …

Yahoo Finance · May 31, 2026
ZVIA
▼ bear…

Zevia PBC (ZVIA): 8 Best Up and Coming Penny Stocks to Buy Now

The panel consensus is overwhelmingly bearish on ZVIA, citing operational execution issues, weak EBITDA, and missed guidance as key concerns. …

Yahoo Finance · May 31, 2026
OKLO NUS
▬ mixed

La energía nuclear es la historia de 2026. Aquí hay 2 acciones para tener durante todo el año.

Nuclear Is the Energy Story of 2026. Here Are 2 Stocks to Own All Year.

The panel consensus is bearish on Oklo and NuScale's near-term prospects due to regulatory, financing, and fuel supply hurdles. While …

Nasdaq · May 31, 2026
JNJ
▬ mixed

J&J Fase 1b/2 OrigAMI-4: Amivantamab Subcutáneo Muestra un ORR del 42% en Cáncer de Cabeza y Cuello

J&J Phase 1b/2 OrigAMI-4: Subcutaneous Amivantamab Shows 42% ORR In Head & Neck Cancer

Johnson & Johnson's amivantamab showed promising results with a 42% ORR in heavily pretreated head and neck cancer, but further …

Nasdaq · May 31, 2026
ICE
▬ mixed

"ONG con buen financiamiento" detrás del caos anti-ICE en Newark; Bessent señala una represión de las organizaciones sin fines de lucro

"Well-Funded" NGO Machine Behind Newark Anti-ICE Chaos; Bessent Signals Nonprofit Crackdown

The panel discusses potential impacts of IRS guidance on nonprofits tied to activism, with risks including capital flight, reputational damage, …

ZeroHedge · May 31, 2026
ASTS LUNR INTU
▬ mixed

2 Acciones Espaciales para Comprar Antes de la OPI de SpaceX el 12 de Junio

2 Space Stocks to Buy Before the SpaceX IPO on June 12

The panel consensus is bearish on AST SpaceMobile (ASTS) and Intuitive Machines (LUNR), citing significant execution risks, uncertain revenue visibility, …

Nasdaq · May 31, 2026
S U
▬ mixed

La mejor criptomoneda para comprar con $1,000 ahora mismo

The Best Cryptocurrency to Buy With $1,000 Right Now

The panel is divided on Solana's investment merit, with concerns about repeated outages, unclear ETF timeline, and intense competition from …

Nasdaq · May 31, 2026
NVDA
▬ mixed

Nvidia Recently Plowed $3.8 Billion Into These 2 Artificial Intelligence (AI) Stocks

Despite strategic positioning in AI infrastructure, Nvidia's investments in CoreWeave and Coherent pose significant risks, including high leverage, potential dilution, …

Nasdaq · May 31, 2026
▼ bear…

Social Security Work Rules You Must Understand Before Working in Retirement

The panel generally agreed that while working in retirement can potentially increase Social Security benefits, the current system presents significant …

Nasdaq · May 31, 2026
PFE
▬ mixed

La Combinación de BRAFTOVI de Pfizer Casi Duplica la Supervivencia Libre de Progresión en el Cáncer Colorrectal Metastásico con BRAF V600E

Pfizer's BRAFTOVI Combo Nearly Doubles PFS In BRAF V600E Metastatic Colorectal Cancer

Pfizer's BREAKWATER Cohort 3 data shows promising results in first-line BRAF V600E mCRC, with a significant PFS benefit and encouraging …

Nasdaq · May 31, 2026
LLY
▬ mixed

Retevmo de Eli Lilly, Fase 3 LIBRETTO-432, Reduce el Riesgo de Recurrencia en un 83% en NSCLC en Etapa Temprana RET+

Eli Lilly's Retevmo Phase 3 LIBRETTO-432 Cuts Recurrence Risk 83% In RET+ Early-Stage NSCLC

Eli Lilly's selpercatinib (Retevmo) showed promising results in a Phase 3 trial, reducing recurrence risk by 83% in early-stage RET-positive …

Nasdaq · May 31, 2026